Hutchison China Meditech Ltd., of Shanghai, closed its underwritten public offering of American depositary shares (ADS) on the Nasdaq Global Select Market, previously announced by Chi-Med at $26.50 per ADS, raising gross proceeds of approximately $301.3 million before deducting underwriting discounts, commissions and offering expenses. BofA Merrill Lynch and Deutsche Bank Securities (in alphabetical order) are acting as joint global coordinators and joint bookrunners for the Offering. Stifel, Canaccord Genuity, Panmure Gordon (UK) Limited and CITIC CLSA are acting as co-managers for the offering.